Medinews· @Medinews_ · X·· 2 天前评分70
正文 · 机器翻译
III期#NATALEE研究，在#ESMO26上公布了6年随访分析结果。
详情请见此处：https://www.medinews.it/comunicati/ribociclib-dimostra-un-beneficio-in-termini-di-sopravvivenza-globale-nella-piu-ampia-popolazione-di-pazienti-con-tumore-della-mammella-hr-her2%e2%88%92-in-fase-iniziale/
@myESMO
42 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：Medinews · x.com